Literature DB >> 29715096

Moesin Involvement in Oral Carcinogenesis of the Lower Lip.

Agnes Assao1, Paula Midori Yoshino1, Maria Carolina Malta Medeiros1, André Lopes Carvalho2, Fernando Augusto Soares3, Luiz Paulo Kowalski4, Denise Tostes Oliveira5.   

Abstract

BACKGROUND/AIM: This study analyzed moesin immunoexpression in 91 lip squamous cell carcinomas and its influence in patients' prognosis.
MATERIALS AND METHODS: Moesin immunoexpression was evaluated at the invasive tumor front by a semi-quantitative score method. The association of moesin with the clinicopathological variables was analyzed by the Chi-square test, the survival rates were calculated by Kaplan-Meier and the survival curves compared using the log-rank test.
RESULTS: The expression of moesin was strong at the invasive tumor front and weak/negative in differentiated cells such as keratin pearls. There was no association between moesin expression and the clinicopathological variables, but there was a tendency for patients with lip cancer and strong moesin expression to have lower 5- and 10-year overall and disease-free survival rates.
CONCLUSION: Our results confirm the participation of moesin in oral carcinogenesis and suggest that this protein can influence the survival rates of patients with lip squamous cell carcinoma. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Oral cancer; biomarkers; moesin; squamous cell carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29715096     DOI: 10.21873/anticanres.12518

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Moesin Serves as Scaffold Protein for PD-L1 in Human Uterine Cervical Squamous Carcinoma Cells.

Authors:  Rina Doukuni; Takuro Kobori; Chihiro Tanaka; Mayuka Tameishi; Yoko Urashima; Takuya Ito; Tokio Obata
Journal:  J Clin Med       Date:  2022-07-01       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.